Muscle-building supplement use and increased risk of testicular germ cell cancer in men from Connecticut and Massachusetts

N Li1,2, R Hauser3, T Holford1, Y Zhu1, Y Zhang1, B A Bassig1, S Honig4, C Chen5, P Boyle6, M Dai2, S M Schwartz5, P Morey3, H Sayward1, Z Hu7, H Shen7, P Gomery8 and T Zheng*1

1Department of Environmental Health Sciences, Yale School of Public Health, 60 College Street, LEPH 440, New Haven, CT 06520-8034, USA; 2National Office for Cancer Prevention and Control, China Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China; 3Department of Environmental Health Sciences, Harvard School of Public Health, Boston, MA 02115, USA; 4Department of Urology, Yale School of Medicine, New Haven, CT 06510, USA; 5Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA; 6International Prevention and Research Institute, Lyon 69006, France; 7Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, Nanjing Medical University, Nanjing 210029, China and 8Department of Urology, Massachusetts General Hospital, Boston, MA 02114, USA

Background: No analytic epidemiological study has examined the relationship between use of muscle-building supplements (MBSs) and testicular germ cell cancer (TGCC) risk.

Methods: We conducted a population-based case–control study including 356 TGCC cases and 513 controls from Connecticut and Massachusetts.

Results: The odds ratio (OR) for ever use of MBSs in relation to risk of TGCC was significantly elevated (OR = 1.65, 95% confidence interval (CI): 1.11–2.46). The associations were significantly stronger among early users, men with more types of MBSs used, and longer periods of use.

Conclusions: MBS use is a potentially modifiable risk factor that may be associated with TGCC.

Testicular germ cell cancer (TGCC) is the most common solid malignancy in men aged 15–39 years (Ferlay et al, 2012). The age-adjusted incidence of TGCC in the United States (US) based on data from the Surveillance Epidemiology and End Results (SEER) program has been increasing, growing from 3.7 out of 100 000 in 1975 to 5.9 out of 100 000 in 2011 (SEER Program, 2014).

Cryptorchidism, abnormal development of the testicles, and family history are known risk factors for TGCC (Greene et al, 2010; Schnack et al, 2010; Lip et al, 2013), but these known factors cannot explain the increasing trend of TGCC given that only a relatively small percentage of cases have a history of cryptorchidism (~10%) (Ferguson and Agoulnik, 2013).

Use of performance-enhancing substances has become increasingly popular in the US population (Andres et al, 1999; Froiland et al, 2004; Bemben and Lamont, 2005). Some previous evidence has indicated that certain ingredients of muscle-building supplements (MBSs) may be related to testicular damage (Yu and Deng, 2000; Han et al, 2013; National Center for Biotechnology Information, 2014). It is therefore biologically plausible that MBS use could be associated with the risk of TGCC. A case series that evaluated MBS use among 129 TGCC cases in the United States observed that a relatively high percentage of cases (~20%) had used some form of supplements, but no control group was included in this study for comparison (Chang et al, 2005). To better understand the
role of MBS use on the risk of TGCC, we conducted a population-based case–control study in Connecticut (CT) and Massachusetts (MA).

**MATERIALS AND METHODS**

**Study population.** Subjects for this population-based case–control study were recruited between 2006 and 2010 among male residents of CT and MA. The incident cases included newly diagnosed patients with TGCC (International Classification of Diseases for Oncology Morphology Codes 9906–9910) identified using the Yale Comprehensive Cancer Center’s Rapid Case Ascertainment Shared Resource (RCA) and the Massachusetts Cancer Registry over the same time period.

The eligibility criteria for cases in the study included having a histologically confirmed TGCC (Stage 0–IV) diagnosed during 2006–2010, no previous cancer diagnoses except for non-melanoma skin cancer, being a male resident of CT or MA and between the ages of 18–55 at diagnosis, alive and competent to answer questions at the time of interview, and able to speak English in order to complete the interview. Population-based controls were identified among English-speaking male residents of CT and MA between the ages of 18–55 at the time of the interview, using random digit dialing. Controls were frequency-matched to cases sampling on the basis of age categories, and individuals with a previous history of cancer with the exception of non-melanoma skin cancer were excluded as potential controls. The study was approved by the Institutional Review Boards of Yale University, the Connecticut Department of Public Health Human Investigation Committee, the Harvard School of Public Health Human Subject Committee, the Massachusetts Department of Public Health, Dana Farber Cancer Institute, and the 28 participating hospitals in Connecticut.

**Data collection.** All subjects included in the study completed an in-person and standardised, structured questionnaire implemented by trained study interviewers. A total of 356 cases and 513 controls were included in the present study with a participation rate of 57.4% for the cases and 47.8% for the controls. The interview included questions about a wide variety of characteristics suspected to be associated with the risk of TGCC, including MBS. MBS use was defined as use for at least once a week for 36 months (OR = 2.55, 95% CI: 1.30–5.91), in those who used MBS containing ingredients of both creatine and proteins (OR = 2.21, 95% CI: 1.34–3.63), in men who ever used MBS (OR = 2.77, 95% CI: 1.30–5.91), and in those who used MBS for >36 months (OR = 2.56, 95% CI: 1.39–4.74) (Table 2).

**Statistical analysis.** Unconditional logistic regression models were used to evaluate the associations between the use of MBS and the risk of TGCC. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated for ever vs never MBS use and for several additional metrics in relation to risk of TGCC. These metrics included age at first use, number of MBS products used, and duration of use. Polytomous logistic regression models and then hierarchical coefficients tests were used to evaluate the associations between the use of MBS and the risk of TGCC by subtypes (seminoma and non-seminoma, each vs controls). P < 0.05 was the criterion of statistical significance, and all statistical tests were two sided. Statistical analyses were conducted using Stata Version 10.0 software (Stata, College Station, TX, USA).

**RESULTS**

As shown in Table 1, the cases were slightly younger and more likely to be white than the controls. The prevalence of cryptorchidism and injury to the testes or groin was higher in cases than that in controls. However, years of education, prevalence of tobacco smoking, prevalence of alcohol drinking, and height were similar in cases and controls (Table 1).

Adjusted ORs for the association between use of MBS and risk of TGCC are presented in Table 2. Compared with men who never used MBS, the OR for ever use in relation to TGCC risk was 1.65 (95% CI: 1.11–2.46) (Table 2). Compared with men who did not use MBS, the strongest associations with risk of TGCC were observed in those who used MBS before the age of 25 years (OR = 2.21, 95% CI: 1.34–3.63), in men who ever used ≥ 2 types of MBS (OR = 2.77, 95% CI: 1.30–5.91), and in those who used MBS for >36 months (OR = 2.56, 95% CI: 1.39–4.74) (Table 2).

Analyses by TGCC subtype suggested similar associations between use of MBS and the risk of seminoma and non-seminoma (Table 3) (all the P-values for hierarchical coefficients tests were >0.05). We further conducted exploratory stratified analyses examining associations with TGCC for the major types of MBS use reported by the study population and found that the use of MBS containing ingredients of both creatine and proteins increased the risk of TGCC significantly (OR = 2.55, 95% CI: 1.05–6.15).

### Table 1. Characteristics of TGCC Cases and Controls in a Population-Based Case–Control study, Connecticut and Massachusetts, 2006–2010

| Characteristics | Cases (%) (n = 356) | Controls (%) (n = 513) |
|-----------------|---------------------|------------------------|
| Age (years, means) | 35.42 | 38.34 |
| Race | | |
| Whites | 338 (94.94) | 459 (89.47) |
| Others | 18 (5.06) | 54 (10.53) |
| Years of education | | |
| ≤12 years | 101 (28.37) | 137 (26.71) |
| >12 years | 255 (71.63) | 376 (73.29) |
| Tobacco smoking | | |
| Never | 224 (62.92) | 309 (60.23) |
| Ever | 132 (37.08) | 204 (39.77) |
| Alcohol drinking | | |
| Never | 21 (5.90) | 28 (5.46) |
| Ever | 335 (94.10) | 485 (94.54) |
| Height at reference date | | |
| ≤68 inches | 90 (25.28) | 143 (27.88) |
| 69–70 inches | 98 (27.53) | 125 (24.37) |
| 71–72 inches | 93 (26.12) | 146 (28.46) |
| >72 inches | 75 (21.07) | 98 (19.10) |
| Missing | 0 (0.00) | 1 (0.19) |
| Undescended testes or cryptorchidism | | |
| No | 312 (87.64) | 500 (97.47) |
| Yes | 41 (11.52) | 11 (2.14) |
| Missing | 3 (0.84) | 2 (0.39) |
| Family history of TGCC | | |
| No | 252 (70.79) | 408 (79.53) |
| Yes | 7 (1.97) | 4 (0.78) |
| Missing | 97 (27.25) | 101 (19.69) |
| Injury to testes or groin | | |
| No | 213 (59.83) | 358 (69.79) |
| Yes | 142 (39.89) | 154 (30.02) |
| Missing | 1 (0.28) | 1 (0.19) |
| Vigorous exercise or sports activities | | |
| No exercise | 19 (5.34) | 25 (4.87) |
| ≤12 h per month | 89 (25.00) | 162 (31.58) |
| >12 h per month | 119 (33.43) | 161 (31.38) |
| Missing | 129 (36.24) | 165 (32.16) |

Abbreviation: TGCC = testicular germ cell cancer.

*Injury to testes or groin that prevented normal activities for at least 5 min.

†Vigorous exercise or sports activities in the past 2 years.
Table 2. Association Between MBS Use and the Risk of TGCC, Connecticut and Massachusetts, 2006–2010

| MBS use | No. of cases (%) | No. of controls (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|------------------|---------------------|-------------|-----------------------|
| Never  | 289 (81.18)      | 451 (87.91)         | 1           | 1.69 (1.16–2.46)      | 1.65 (1.11–2.46) |
| Ever   | 67 (18.82)       | 62 (12.09)          | 1           | 1                     | 1                     |

Age at first use (13–50 years)

| MBS use | No. of cases (%) | No. of controls (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|------------------|---------------------|-------------|-----------------------|
| Never   | 289 (81.18)      | 451 (87.91)         | 1           | 1                     | 1                     |
| >25 years | 17 (4.78)      | 30 (5.85)            | 0.88 (0.48–1.63) | 1.00 (0.52–1.91)    |
| <25 years | 50 (14.04)     | 32 (6.24)            | 2.44 (1.53–3.89) | 2.21 (1.34–3.63)    |

Number of types used

| MBS use | No. of cases (%) | No. of controls (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|------------------|---------------------|-------------|-----------------------|
| Never   | 289 (81.18)      | 451 (87.91)         | 1           | 1                     | 1                     |
| 1 type  | 42 (11.8)        | 51 (9.94)            | 1.29 (0.83–1.98) | 1.38 (0.87–2.17)    |
| >2 types| 25 (7.02)        | 11 (2.14)            | 3.55 (1.72–7.32) | 2.77 (1.30–5.91)    |

Duration of use

| MBS use | No. of cases (%) | No. of controls (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|------------------|---------------------|-------------|-----------------------|
| Never   | 289 (81.18)      | 451 (87.91)         | 1           | 1                     | 1                     |
| ≤12 months | 22 (6.18)      | 32 (6.24)            | 1.07 (0.61–1.88) | 1.13 (0.63–2.05)    |
| 13–35 months | 32 (8.99)     | 19 (3.70)            | 2.63 (1.46–4.73) | 2.56 (1.39–4.74)    |

Table 3. Association Between MBS Use and the Risk of TGCC, by Histological Type, Connecticut and Massachusetts, 2006–2010

| MBS use | No. of controls (%) | No. (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|---------------------|---------|-------------|-----------------------|
| Seminoma | 451 (87.91)        | 154 (81.48) | 1.65 (1.05–2.60) | 1.90 (1.17–3.08) | 29 (19.59) | 1.77 (1.09–2.88) |
| Non-seminoma | 62 (12.09)      | 35 (18.52) | 1           | 1                     | 1                     |

Age at first use

| MBS use | No. of controls (%) | No. (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|---------------------|---------|-------------|-----------------------|
| Seminoma | 451 (87.91)        | 154 (81.48) | 0.98 (0.47–2.04) | 1.12 (0.51–2.45) | 6 (4.05) | 0.76 (0.31–1.86) |
| Non-seminoma | 30 (5.85)       | 10 (5.29) | 2.29 (1.31–3.98) | 2.63 (1.45–4.76) | 23 (15.54) | 2.72 (1.54–4.83) |

Number of types used

| MBS use | No. of controls (%) | No. (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|---------------------|---------|-------------|-----------------------|
| Seminoma | 451 (87.91)        | 154 (81.48) | 1.26 (0.74–2.15) | 1.58 (0.90–2.76) | 18 (12.16) | 1.34 (0.75–2.37) |
| Non-seminoma | 32 (6.24)       | 25 (13.23) | 3.46 (1.52–7.89) | 3.23 (1.35–7.75) | 11 (7.43) | 3.79 (1.60–8.95) |

Duration of use

| MBS use | No. of controls (%) | No. (%) | OR (95% CI) | Adjusted OR (95% CI)* |
|---------|---------------------|---------|-------------|-----------------------|
| Seminoma | 451 (87.91)        | 154 (81.48) | 0.82 (0.38–1.76) | 1.03 (0.47–2.28) | 12 (8.11) | 1.42 (0.71–2.84) |
| Non-seminoma | 32 (6.24)       | 9 (4.76) | 2.93 (1.51–5.68) | 3.33 (1.64–6.74) | 12 (8.11) | 2.39 (1.13–5.07) |

Abbreviations: CI = confidence interval; MBS = muscle-building supplement; OR = odds ratio; TGCC = testicular germ cell cancer.

Adjusted for age (continuous variable), race (Whites vs others), years of education (12 vs >12 years), tobacco smoking (ever vs never), alcohol drinking (ever vs never), height (<68, 69–70, 71–72, >72 inches), undescended testes or cryptorchidism (no, yes, missing), injury to testes or groin (no, yes, missing), vigorous exercise or sports activities (no exercise, ≤12 per month, >12 per month, missing), and family history of TGCC (no, yes, missing).

The values in bold indicate statistically significant associations.

DISCUSSION

MBS use was found to be associated with an increased risk of TGCC. The associations were stronger among early users, men using ≥2 types of MBS, and longer use of MBS. To our knowledge, this is the first analytical epidemiological study to explore the association between MBS use and the risk of TGCC.

Little is known about the aetiology of TGCC, particularly factors that would explain the rapid incidence increases in this disease. The increasing trends for seminoma and non-seminoma are similar, suggesting that they may share some important causal factors (Richiardi et al, 2004), which was also suggested in our present study as the risk associated with MBS use was similar by subtype. In addition to the ingredients in MBS that are known, there are also so-called natural components that may act as artificial hormones and other impurities that may vary by product. It has been documented that some commercially available supplement products contain less active ingredients than indicated on the product label or ‘hidden’ ingredients that are not listed on the label (Green et al, 2001). An international study found that ~15% of commercially available non-hormonal supplements contained undeclared anabolic androgenic steroids, including prohormones of nandrolone, which have been associated with development of testicular cancer in rats (Geyer et al, 2004; Chimento et al, 2012). Whether those ingredients have a role in the risk of TGCC in humans is currently unclear. Therefore, our preliminary findings suggest that the long-term
effects of MBS use, such as increased cancer risk, and its mechanisms, need to be further investigated. Of particular interest would be further evaluation of the potential effects of the combined use of multiple types of MBS at the same time.

In our study, nearly 20% of cases with TGCC had used MBS, which was similar to the previous case series study (Chang et al., 2005). Despite the fact that self-reported questionnaire data was used in our study, differential recall of MBS use by the cases and controls is unlikely as an association with MBS has not previously been reported in an epidemiological study and therefore this exposure would likely not be a suspected risk factor for TGCC among study subjects at the time of the interview. We also note that the associations with MBS use for TGCC remained significantly elevated after adjustment of the models for major potential confounders, with risks of over twofold persisting in the adjusted models for the earliest and longest users of MBS. Strengths of our population-based study include the use of standardised in-person interviews conducted by trained interviewers that included detailed questions on lifetime MBS use and inclusion of only histologically confirmed incident TGCC cases in our study, which minimised the possibility of disease misclassification.

In conclusion, our study suggests that MBS use might contribute to the risk of TGCC, both seminoma and non-seminoma. Considering the magnitude of the association and the observed dose–response trends, MBS use may be an important and potentially modifiable exposure that could have important scientific and clinical importance for preventing TGCC development if this association is confirmed by future studies.

ACKNOWLEDGEMENTS

The cooperation of 28 Connecticut hospitals, including Charlotte Hungerford Hospital, Bridgeport Hospital, Danbury Hospital, Hartford Hospital, Middletown Hospital, New Britain General Hospital, Bradley Memorial Hospital, Yale/New Haven Hospital, St. Francis Hospital and Medical Center, St. Mary’s Hospital, Hospital of St. Raphael, St. Vincent’s Medical Center, Stamford Hospital, William W. Backus Hospital, Windham Hospital, Eastern Connecticut Health Network, Griffin Hospital, Bristol Hospital, Johnson Memorial Hospital, Day Kimball Hospital, Greenwich Hospital, Lawrence and Memorial Hospital, Milford Hospital, New Milford Hospital, Norwalk Hospital, MidState Medical Center, John Dempsey Hospital and Waterbury Hospital, in allowing patient access, is gratefully acknowledged. Rajni Mehta from the Yale Comprehensive Cancer Center’s RGA provided great assistance in both IRB approvals and field implementation of the study. Certain data used in this study were obtained from the Connecticut Tumor Registry located in the Connecticut Department of Public Health. The author(s) assume(s) full responsibility for analyses and interpretation of these data.

This work was partly supported by the National Cancer Institute (grant CA104786); Fogarty training grants from the National Institutes of Health (D43TW 008323, D43TW 007864-01); The National Natural Science Fund from the National Natural Science Foundation of China (grant 81172757); The Beijing Natural Science Foundation (grant 7123225); and the Beijing Nova Program (grant xx2012067).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Andres LP, Sacheck J, Tapia S (1999) A review of creatine supplementation: side effects and improvements in athletic performance. Nutr Clin Care 2(2): 73–81.

Bemben MG, Lamont HS (2005) Creatine supplementation and exercise performance: recent findings. Sports Med 35(2): 107–125.

Chang SS, Ivey B, Smith Jr. JA, Roth BJ, Cookson MS (2005) Performance-enhancing supplement use in patients with testicular cancer. Urology 66(2): 242–245.

Chimento A, Sirianni R, Zolea F, De Luca A, Lanzino M, Catalano S, Ando S, Pezzi V (2012) Nandrolone and stanozolol induce Leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system. J Cellular Physiol 227(5): 2079–2088.

Ferguson L, Agoulnik AI (2013) Testicular cancer and cryptorchidism. Front Endocrinol 4: 32.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer: Lyon, France. Available from http://globocan.iarc.fr. Accessed March 2014.

Froiland K, Koszewski W, Hingst J, Kopecky L (2004) Nutritional supplement use among college athletes and their sources of information. Int J Sport Nutr Exerc Metab 14(1): 104–120.

Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schanzer W (2004) Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int J Sports Med 25(2): 124–129.

Green GA, Catlin DH, Starcevic B (2001) Analysis of over-the-counter dietary supplements. Clin J Sport Med 11(4): 254–259.

Greene MH, Kratz CP, Mai PL, Mueller C, Peters JA, Bratslavsky G, Ling A, Choyke PM, Premkumar A, Bracci J, Watkins RJ, McMaster ML, Korde LA (2010) Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer 17(2): R109–R121.

Han SP, Zhou DX, Lin P, Qin Z, An L, Zheng LR, Lei L (2013) Formaldehyde exposure induces autophagy in testis tissues of adult male rats. Environ Toxicol; doi:10.1002/tox.21910.

Lip SZ, Murchison LE, Cullis PS, Govan L, Carachi R (2013) A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child 98(1): 20–26.

National Center for Biotechnology Information (2014) PubChem Compound Database. Androstenedione http://pubchem.ncbi.nlm.nih.gov/compound/androstenedione#section=Drug-and-Medication-Information. Accessed June 2014.

Richardi L, Bellocco R, Adami HO, Torrang A, Barlow I, Hakulinen T, Rahu M, Stengrevics A, Hreti H, Tretli S, Kunitnatis J, Tyczynski JE, Akre O (2004) Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev 13(12): 2157–2166.

Schnack TH, Poulsen G, Myrup C, Wohlfahrt J, Melbye M (2010) Familial coaggregation of cryptorchidism, hypospadias, and testicular germ cell cancer: a nationwide cohort study. J Natl Cancer Inst 102(3): 187–192.

SEER Program (2014) Surveillance, Epidemiology, and End Results (SEER) Program www.seer.cancer.gov/SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2013 Sub (1973-2011) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission.

Yu PH, Deng Y (2000) Potential cytotoxic effect of chronic administration of creatine, a nutrition supplement to augment athletic performance. Med Hypotheses 54(5): 726–728.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.